Many large pharmaceutical companies are focusing on lucrative
emerging markets like India, China and Brazil, to name a few.
Emerging markets are slowly and steadily gaining more importance
and several companies are now shifting their focus to these areas.
) is no exception to the above mentioned trend. In a bid to expand
its footprint in India, the biopharmaceutical major extended its
tie-up with Syngene International by five years. Financial details
of the extended pact were not revealed. Syngene, a unit of Biocon,
is India's largest contract research organization.
The research collaboration between the companies has been in
existence since 2007. The companies have been focusing on
developing integrated capabilities in fields like medicinal and
process chemistry, biology and biotechnology. The companies worked
in Bangalore at the Biocon Bristol-Myers Squibb Research Center
This drug discovery partnership has so far yielded six candidates
for further study. The Indian collaboration has helped
Bristol-Myers to reduce the time and costs pertaining to the
advancement of candidates to first-in-human studies from the
Bristol-Myers stated in its press release that following the pre
clinical work done at BBRC, Bristol-Myers was able to advance the
development of most of its small molecule candidates further. With
the initial phase of the partnership yielding such promising
results, we believe that the extension of the pact is a logical
Apart from Bristol-Myers, companies like
) are also focusing on the Indian market which offers great
Bristol-Myers currently carries a Zacks Rank #3 (Hold). A
better-ranked biopharma stock is
) with a Zacks Rank #1 (Strong Buy).
Want the latest recommendations from Zacks Investment Research?
Today, you can download 7 Best Stocks for the Next 30 Days.
Click to get this free report
BRISTOL-MYERS (BMY): Free Stock Analysis Report
SANOFI-AVENTIS (SNY): Free Stock Analysis
GILEAD SCIENCES (GILD): Free Stock Analysis
MYLAN INC (MYL): Free Stock Analysis Report
To read this article on Zacks.com click here.